A One Year Open Label, Non-comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration (LIC) of Repeated Doses of 5-30mg/kg/Day ICL670 Relative to Deferoxamine (DFO) in Sickle Cell Disease (SCD) Patients With Transfusional Hemosideresis (THS) [Amendment 3: Extension Prolonged to 4-years]
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemosiderosis
- Focus Adverse reactions
- Sponsors Novartis
Most Recent Events
- 21 Mar 2016 New source identified and integrated (ISRCTN: Current Controlled Trials; 05896089)
- 10 Sep 2014 New trial record
- 10 Sep 2014 New trial record